

13 October 2026

Identifai Genetics lists on the ASX following a \$10 million IPO to advance US prenatal screening strategy

IPO funding to advance clinical validation and US laboratory readiness for Windrose™, a prenatal genetic screening platform designed to assess selected inherited conditions from a single maternal blood sample.

Highlights:

- Identifai Genetics commences trading on the ASX under the code ID1, following a successful IPO raising A\$10 million at A\$0.20 per share.
- Flagship proprietary technology, Windrose™, combines genomic sequencing, artificial intelligence and machine learning to assess selected inherited genetic conditions affecting the fetus, using a single maternal blood sample without requiring a paternal sample in its screening workflow.
- Designed for sample collection from approximately nine weeks of pregnancy, with the aim of giving clinicians and families earlier information to guide further investigation and care planning.
- Technology originated from research at Tel Aviv University and is supported by an intellectual property portfolio comprising 11 patent families, together with approximately a decade of accumulated research.
- The United States is the Company's first target commercialisation market. IPO proceeds will support US laboratory readiness, assay validation, a planned multicentre clinical validation study and further product development.

Identifai's CEO, Eyal Miller, commented on the milestone:

"Our ASX listing is an important step in translating Identifai's research into a product intended for use in prenatal care. We thank our shareholders for supporting the Company and welcome our new investors as we enter this next phase.

The United States is our first target commercial market. Our immediate priorities are progressing laboratory readiness, the planned clinical validation programme and staged product releases, while pursuing commercial partnerships.



Our ambition is to make earlier, clinically relevant genetic information more accessible through a single maternal blood sample. Our immediate focus is on generating the evidence and establishing the laboratory capabilities needed to support that ambition. We look forward to keeping shareholders informed as we progress through these milestones.”

Identifai Genetics Limited (**ASX:ID1**) (“**Identifai**” or the “**Company**”), a biotechnology company developing non-invasive prenatal genetic screening technology, is pleased to announce the commencement of trading on the Australian Securities Exchange (“**ASX**”) today, 13 October 2026, under the ticker code ID1, following the successful Initial Public Offering (“**IPO**”) raising A\$10 million at A\$0.20 per share. Aesir Corporate acted as Lead Manager to the IPO.

The listing marks an important milestone in Identifai’s development, providing capital to advance clinical validation of its Windrose™ platform and prepare for its launch in the United States.

Identifai Genetics began with a decade of research into what prenatal screening could become, not just telling families what’s possible, but what’s actionable. That research has become Windrose™.

Identifai’s objective is to make clinically relevant fetal genetic information available earlier in pregnancy through a single maternal blood sample. Its development strategy focuses on selected inherited conditions for which an earlier finding may support further investigation, specialist referral, delivery planning or preparation for neonatal care. All of which are important for an expectant parent.

Windrose™ technology and clinical purpose

During pregnancy, maternal blood contains a mixture of maternal and fetal cell-free DNA. Windrose™ combines genomic sequencing with proprietary computational analyses, including artificial intelligence and machine learning, to predict fetal genetic variants within that mixture and assess selected inherited conditions.

The workflow uses a single maternal blood sample, without requiring a paternal sample, and sample collection is designed to begin at approximately nine weeks of pregnancy. The platform’s genome wide analytical approach provides the technological foundation for screening selected clinically relevant conditions.

Identifai is developing Windrose™ to provide information that can support clinician-led decisions

about further testing and care. For some conditions, earlier identification of a potential genetic finding may provide additional time for genetic counselling, diagnostic investigation and coordination of specialist care before delivery or during the neonatal period.

The technology originated from research by Professor Noam Shomron and Dr Tom Rabinowitz at Tel Aviv University and was established in 2021 by ShizimVS Innovation Center. Identifai's intellectual property portfolio comprises 11 patent families, supported by over 10 years of experience.

Co-founder and Chief Scientific Officer Professor Noam Shomron PhD leads the scientific programme, alongside CEO Eyal Miller and the Company's research and operations team. Mr. Yossi Bornstein is a Co-Founder of the Company and serves as Chairman of the Board.

Identifai's Co-founder and Chief Scientific Officer, Professor Noam Shomron, commented:

"Our research began with a clear objective, to obtain more meaningful information about fetal genetics from a maternal blood sample, early enough for that information to help guide clinical care. Windrose™ brings together genomic sequencing and computational analysis to address that challenge.

The importance of earlier information is the time it may give clinicians and families to investigate a finding, obtain specialist advice and prepare an appropriate care plan. We are focused on selected inherited conditions where that additional time could be clinically valuable.

This listing supports the next stage of our work, building the clinical evidence needed to evaluate Windrose™ in its intended setting and advancing the technology towards clinical use."

Next steps:

Identifai is pursuing a US-first commercialisation strategy, with preparations focused on the laboratory-development test pathway and the laboratory, validation and operational requirements.

- Advance US laboratory readiness and assay validation, including the applicable Clinical Laboratory Improvement Amendments ("CLIA") certification requirements.
- Progress the planned US multicentre clinical validation study, targeting approximately 600 participants, to further evaluate Windrose™ in its intended clinical setting.

- Prepare for staged introduction, subject to completion of relevant validation work and satisfaction of applicable regulatory and laboratory requirements.
- Continued development of the next-generation Windrose™+ programme
- Pursue commercial partnerships to support the Company's US market entry and integration into prenatal care pathways.

The Company will update the market as material development, clinical validation and commercial milestones are achieved.

This announcement has been approved by the Board of Directors.

For further information, contact:

Damian Black

Investor & Shareholder Relations

Email: corporate@aesircapital.com.au

Jane Morgan

Investor & Media Relations

Email: jm@janemorganmanagement.com.au

About Identifai Genetics

Identifai Genetics Limited (ASX:ID1) is developing prenatal genetic screening technology that combines genomic analysis, artificial intelligence and machine learning to assess selected inherited conditions affecting the fetus.

Its first product, Windrose™, is designed around a single maternal blood sample, without requiring a paternal sample in the intended screening workflow. The Company is focused on commercialising its technology in the United States first, with the aim of providing information earlier in pregnancy to support clinician-led investigation and care planning. Screening findings may require confirmatory diagnostic testing.

<https://identifai-genetics.com/>

